Move for Your Mind - Pilot Trial (MFYM - P)
Home Exercise, Vitamin D and Dalcroze Eurhythmics for Seniors With Mild Cognitive Impairment (MCI) or Mild Dementia
Move for your mind is a single blind, 3-arm randomized controlled clinical pilot trial. The study aims to test the effect of a weekly Dalcroze eurhythmics program (arm 1) and a home strength exercise program (arm 2) against control (no exercise) on the rate of falling, quality of life, gait performance and cognitive function. All groups receive vitamin D. In addition the study shall test the feasibility of the recruitment and the interventions in this target population.
The study includes 60 seniors, age 65 and older, with mild cognitive impairment or mild dementia. Participants are recruited by the memory clinic of City Hospital Waid.
During the 12 months follow-up, participants will have 3 clinical visits (baseline, 6 and 12 month). Despite major efforts the target population is very difficult to recruit and adherence to treatment is low. We therefore decided to stop recruitment and to use this trial as a pilot trial for future clinical trials of the same topic.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Primary objective To test whether the Jaques-Dalcroze eurhythmics program (1 hour a week for 12 months) and/or the simple home exercise program (3 × 30 min a week for 12 months) will decrease rate of falls in seniors with MCI or mild dementia compared with the control group.
Secondary objectives Objective 1: To test whether the Jaques-Dalcroze eurhythmics program (1 hour a week for 12 months) and/or the simple home exercise program (3 × 30 min a week for 12 months) decreases 12-month risk of falling at least once in seniors with MCI or mild dementia compared with the control group.
Objective 2: To test whether the Jaques-Dalcroze eurhythmics program (1 hour a week for 12 months) and/or the simple home exercise program (3 × 30 min a week for 12 months) improves cognitive func-tion and alertness in seniors with MCI or mild dementia compared with the control group.
Objective 3: To test whether the Jaques-Dalcroze eurhythmics program (1 hour a week for 12 months) and/or the simple home exercise program (3 × 30 min a week for 12 months) decreases gait variability in seniors with MCI or mild dementia compared with the control group.
Objective 4: To test whether the Jaques-Dalcroze eurhythmics program (1 hour a week for 12 months) and/or the simple home exercise program (3 × 30 min a week for 12 months) improves quality of life in seniors with MCI or mild dementia compared with the control group.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Zurich, Suíça, 8037
- Centre on Aging and Mobility, University of Zurich, Waid City Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age 65+ years
- Diagnosed with MCI or mild dementia by the memory clinic of City Hospital Waid
Exclusion Criteria:
-
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Jaques-Dalcroze eurhythmics
Jaques-Dalcroze eurhythmics (60min/wk) + 800 IU Vitamin D3
|
All participants receive a dose of 800 IU vitamin D3 per day as a standard of care.
800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.
Outros nomes:
The Jaques-Dalcroze eurhythmics method includes different courses of motion (multi-task exercises) that are conducted to the rhythm of improvised piano music.
A session starts with a short warm-up that includes simple exercises to get body and mind prepared for the rest of the exercise session.
The complexity of the exercises increases gradually during the session: starting with single tasks and then combining them into a multi-task exercise gradually increasing complexity.
|
|
Experimental: Home exercise program
Home exercise strength program (3x30min/wk) + 800 IU vitamin D
|
All participants receive a dose of 800 IU vitamin D3 per day as a standard of care.
800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.
Outros nomes:
The home exercise program is a strengthening program that will consist of five simple exercises.
|
|
Outro: Vitamin D only
800 IU Vi-De 3
|
All participants receive a dose of 800 IU vitamin D3 per day as a standard of care.
800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Rate of falls (any falls, low trauma falls, injurious falls) during 12 month follow-up
Prazo: at month 2, 4, 6, 8, 10 and 12 after baseline
|
A fall is defined as unintentional coming to rest on the ground, floor, or other lower level (coming to rest against furniture or a wall is not considered a fall).
All reported incident falls will be ascertained every 2 month (phone calls at 2, 4, 8 and 10 months and clinical visits at 6 and 12 months after baseline) with a questionnaire evaluating the circumstances of each fall and injuries associated with it.
Participants will also receive a diary to record any new health event including a fall.
The diary will serve as a supplementary tool to falls evaluation minimizing potential recall bias.
|
at month 2, 4, 6, 8, 10 and 12 after baseline
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of participants who fell at least once during 12 months of follow up
Prazo: at month 2, 4, 6, 8, 10 and 12 after baseline
|
at month 2, 4, 6, 8, 10 and 12 after baseline
|
|
|
Gait variability (stride time, stride length and gait speed)
Prazo: Baseline, 6 & 12 months
|
assessed by a GAITRite analysis system
|
Baseline, 6 & 12 months
|
|
Cognitive function
Prazo: Baseline, 6 & 12 months
|
assessed using the Montreal Cognitive Assessment (MoCA)
|
Baseline, 6 & 12 months
|
|
Alertness
Prazo: Baseline, 6 & 12 months
|
Alertness will be assessed using the two subtests "alertness" and "split alertness" of the test of attentional performance (TAP)
|
Baseline, 6 & 12 months
|
|
Quality of life
Prazo: Baseline, 6 and 12 months
|
evaluated using the SF-36 questionnaire
|
Baseline, 6 and 12 months
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
progression of MCI/mild dementia
Prazo: 6 &12 months
|
any progression of the cognitive disorder to a more severe state ( will be confirmed based on medical records of the memory clinic of Waid City Hospital.
Evaluation of this endpoint will be supported by information from the MoCA and the TAP subtests at baseline, 6, and 12 months clinical visits.
|
6 &12 months
|
|
Musculoskeletal pain
Prazo: baseline, 6 and 12 month
|
assessed using McGill pain map.
Number of painful joints will be assessed using a joint map.
|
baseline, 6 and 12 month
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Heike Bischoff-Ferrari, Prof., Director Geriatric Clinic University Hospital Zurich and Centre on Aging and Mobility, University of Zurich
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Transtornos Mentais, Desordem Mental
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Distúrbios Neurocognitivos
- Distúrbios Cognitivos
- Demência
- Disfunção cognitiva
- Efeitos Fisiológicos das Drogas
- Micronutrientes
- Vitaminas
- Agentes de Conservação da Densidade Óssea
- Hormônios e Agentes Reguladores de Cálcio
- Vitamina D
- Colecalciferol
Outros números de identificação do estudo
- SNCTP000000580
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .